SCHEMBL3369656

SCHEMBL3369656

Cc1ccc(-c2nc(-c3ccccc3)nc(N)c2C#N)cc1

nearest known ligand 0.83

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 10/20 0.83
ADORA2A P29274 9/20 0.83
HSD17B10 Q99714 2/20 0.83
NPSR1 Q6W5P4 2/20 0.62
DPP4 P27487 1/20 0.62
ADORA2B P29275 1/20 0.58
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
SQOR Q9Y6N5 1/20 0.52
HPGD P15428 2/20 0.52
ALDH1A1 P00352 2/20 0.52
CYP1A1 P04798 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP1B1 Q16678 1/20 0.51
ADRA2A P08913 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369377 0.86 ADORA2A (0.74) ADORA1ADORA2AHSD17B10NPSR1DPP4
SCHEMBL3370624 0.82 ADORA1 (0.76) ADORA1ADORA2AHSD17B10NPSR1DPP4
SCHEMBL3369326 0.82 ADORA2A (0.71) ADORA1ADORA2AHSD17B10NPSR1DPP4
SCHEMBL20041347 0.79 ADORA1 (0.77) ADORA1ADORA2AHSD17B10NPSR1MEN1
SCHEMBL13045873 0.78 ADORA1 (0.57) ADORA1ADORA2AHSD17B10NPSR1ADORA2B
SCHEMBL3369169 0.78 ADORA1 (0.71) ADORA1ADORA2AHSD17B10NPSR1DPP4
SCHEMBL396360 0.77 ADORA1 (0.69) ADORA1ADORA2ANPSR1ADORA2BHPGD
SCHEMBL3369578 0.77 DPP4 (1.00) DPP4ALDH1A1CYP1A1CYP1A2CYP1B1
SCHEMBL1895705 0.76 ADORA1 (0.71) ADORA1ADORA2AHSD17B10MEN1KMT2A
SCHEMBL3369158 0.76 ADORA1 (1.00) ADORA1ADORA2AHSD17B10DPP4ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-1324015-C Pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
CN-1630644-A Novel pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2005-06-22 CN disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 ADORA1 134/4885ADORA2A 794/4885HSD17B10 1818/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK ADORA1 207/4885ADORA2A 547/4885HSD17B10 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.